Rajangam Kanya's Insider Trades & SAST Disclosures
Rajangam Kanya's most recent trade in Senti Biosciences Inc. was a trade of 33,000 Common Stock done at an average price of $2.3 . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rajangam Kanya.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 10 Mar 2025 | 33,000 | 33,000 | - | 2.3 | 74,250 | Common Stock | |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 10 Mar 2025 | 33 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 235,088 | 235,088 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 78,363 | 86,984 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Sale of securities on an exchange or to another person at price $ 4.07 per share. | 04 Feb 2025 | 1,297 | 8,803 | - | 4.1 | 5,279 | Common Stock |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 04 Feb 2025 | 182 | 8,621 | - | 4.4 | 795 | Common Stock |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 49,500 | 49,500 | - | - | Common Stock Warrant (right to buy) | |
| Senti Biosciences Inc. | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 33 | 33 | - | - | Series A Convertible Preferred Stock | |
| Turnstone Biologics Corp | Kanya Rajangam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 12,770 | 12,770 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Rajangam Kanya | Chief Medical & Devt. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 152,000 | 152,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Rajangam Kanya | Chief Medical & Devt. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 101,000 | 101,000 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | Kanya Rajangam | Chief Medical & Devt. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Kanya Rajangam | Chief Medical & Devt. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 327,750 | 327,750 | - | - | Stock Option (Right to Buy) | |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 76,800 | 76,800 | - | - | Stock Option (right to buy) | |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 12,800 | 12,800 | - | 0 | Common Stock | |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.28 per share. | 05 Aug 2021 | 10,000 | 0 | - | 37.3 | 372,800 | Common Stock |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 10,000 | 44,054 | - | - | Stock Option (right to buy) | |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.41 per share. | 05 Aug 2021 | 10,000 | 10,000 | - | 0.4 | 4,100 | Common Stock |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 52,500 | 52,500 | - | - | Stock Option (right to buy) | |
| Nkarta Inc | Kanya Rajangam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2020 | 70,600 | 70,600 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges